ArticleMicroorganisms2023
First Detection and Molecular Characterization of
Article in Microorganisms, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Comparative genomics of fatal ST308/O11 Pseudomonas aeruginosa from Egypt characterizes conserved resistance architecture, integron-associated multidrug resistance modules, and blaNDM-1 resistance islands.BMC microbiology · 2026Article
- Comparative genome analysis of carbapenemase-producing Pseudomonas aeruginosa: gene diversity, clonal distribution, and genome dynamics.Molecular genetics and genomics : MGG · 2026Article
- Epidemiological Trends of Carbapenemase-ProducingAntibiotics (Basel, Switzerland) · 2025Article
- Companion Animals as Reservoirs of Multidrug Resistance-A Rare Case of an XDR, NDM-1-ProducingVeterinary sciences · 2025Article
- Insights into the Rising Threat of Carbapenem-Resistant Enterobacterales andAntibiotics (Basel, Switzerland) · 2024Review
- Emergence of NDM-1-ProducingMicroorganisms · 2024Article
- Rapid Reversal of Carbapenemase-ProducingAntibiotics (Basel, Switzerland) · 2024Article
- In Silico Molecular Analysis of Carbapenemase-Negative Carbapenem-ResistantMicroorganisms · 2024Article
- Antimicrobial and Diagnostic Stewardship of the Novel β-Lactam/β-Lactamase Inhibitors for Infections Due to Carbapenem-Resistant Enterobacterales Species andAntibiotics (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of the present study is to report the detection and the molecular characterization of nine
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.